胃癌化疗配合康莱特注射液治疗对免疫细胞活性的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (498 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Kanglaite Injection on immune cell activity in patients with gastric cancer chemotherapy. Methods A total of 84 patients with advanced gastric cancer admitted to the Affiliated Hospital of Jinggangshan University from October 2019 to August 2021 were selected as the research objects. They were divided into two groups by random number table method, with 42 cases in each group. The control group was treated with conventional Docetaxel combined with Cisplatin chemotherapy, and the treatment group was treated with Kanglaite Injection on the basis of the control group. The curative effect was evaluated during 2 cycles of treatment in both groups.Compared the clinical efficacy of the two groups before treatment and after 2 cycles of treatment, compare the immune function levels of the two groups(T lymphocyte subsets[CD3+,CD4+,CD8+,CD4+/CD8+])before treatment and during 2 cycles of treatment, record the occurrence of side effects in the two groups during treatment. Results The disease control rate of patients in the treatment group was higher than that of the control group during the 2 cycles of treatment, and the overall treatment effect was better than that of the control group, the differences were statistically significant (P<0.05).There were no significant differences in the CD3+,CD4+,CD8+,CD4+/CD8+between two groups before treatment(P>0.05). The CD8+ of two groups during the 2 cycles of treatment were higher than those before treatment, and the CD3+,CD4+, CD4+/CD8+ were lower than those before treatment, but the CD8+ of the treatment group was lower than that of the control group, and the CD3+, CD4+, CD4+/CD8+were higher than those of the control group, the differences were statistically significant (P<0.05). During treatment period, the incidence of nausea, vomiting and bone marrow suppression of the treatment group was lower than that of the control group, and the difference was statistically significant (P<0.05).Conclusion Kanglaite Injection assisted in gastric cancer chemotherapy patients can enhance the immune function of patients, improve clinical efficacy, and reduce the occurrence of nausea, vomiting and bone marrow suppression.

Key words： Gastric cancer Chemotherapy Docetaxel Cisplatin Kanglaite Injection Immune function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I13/110

[1]	葛锐，袁艳.复方苦参注射液对胃癌化疗患者Th1/Th2 细胞漂移和骨髓抑制的影响[J].河北医药，2019，41（13）：1970-1973.
[2]	卜晓倩，张俊萍.氟尿嘧啶分别联合伊立替康和奥沙利铂治疗老年晚期胃癌的优劣差异[J].中国药物与临床，2019，19（3）：470-472.
[3]	陈铁，江晓晖，高志斌，等.恒温热灌注联合常规化疗对老年胃癌术后病人免疫功能、相关因子及生存情况的影响[J].实用老年医学，2020，34（3）：254-257.
[4]	张新峰，乔翠霞，程旭锋，等.康莱特注射液联合吉西他滨注射液和替吉奥胶囊治疗晚期胰腺癌的临床研究[J].中国临床药理学杂志，2018，34（2）：111-113.
[5]	李超，陈俊花，吴静.康莱特注射液联合NP 方案化疗对晚期NSCLC 患者免疫状态、炎症因子及生命质量的影响[J].国际肿瘤学杂志，2018，45（9）：535-538.
[6]	中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会胃癌诊疗指南（2018）[M].北京：人民卫生出版社，2018：129.
[7]	蒋琼慧，路泽军，杨平.肿瘤免疫治疗疗效评价标准——iRECIST 解读[J].转化医学杂志，2020，9（1）：57-60.
[8]	张群，朱武，郑佳，等.胃癌患者腹腔热灌注联合全身静脉化疗的临床效果及对免疫功能的影响[J].中国肿瘤临床与康复，2019，26（11）：1196-1199.
[9]	黄晓峰.康莱特联合XELOX 方案治疗进展期胃癌患者的近期疗效及IL-2、IL-10 的影响[J].实用癌症杂志，2018，33（6）：974-976，981.
[10]	薛珊，邢颖，宋华伟.芬戈莫德联合顺铂通过调控COL11A1表达对顺铂耐药胃癌细胞增殖和凋亡的影响[J].实用药物与临床，2020，23（12）：1057-1062.
[11]	刘佳骅，陈奕宽，陈锦先.多西他赛配合雷替曲塞治疗对胃癌晚期患者DKK-1、TFF3 的影响[J].成都医学院学报，2018，13（3）：284-287.
[12]	沈刚，张燕，陈敏斌，等.康莱特注射液联合SOX 方案治疗晚期胃癌的疗效[J].江苏医药，2017，43（13）：919-921.
[13]	孙小纯，林伟强，欧兴义，等.围术期异体红细胞输注对胃癌患者外周血T 细胞亚群及NK 细胞的影响[J].中国医师杂志，2019，21（10）：1477-1480，1485.
[14]	张风宾，王英南，吴忱思，等.康莱特注射液联合顺铂腹腔灌注治疗脾虚湿困型胃癌恶性腹腔积液的临床疗效研究[J].中国全科医学，2018，21（15）：1852-1856.
[15]	李红云.康莱特注射液联合吉西他滨与顺铂化疗方案治疗晚期非小细胞肺癌的临床疗效及其对免疫功能的影响[J].实用心脑肺血管病杂志，2017，25（5）：121-123.